about
A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12.Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations.Cyclodextrin-polysaccharide-based, in situ-gelled system for ocular antifungal delivery.Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer.In Vitro Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops.In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan.Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention.In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan.[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancerLong Survival and Severe Toxicity Under 5-Fluorouracil–Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMSX-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer PatientsPaclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancyAnti-EGFR therapy in first-line colorectal cancer[Ophthalmic formulations new goals]A modified protocol for rapid desensitization to chemotherapy agents
P50
Q34563854-B1E56E2F-C692-4E94-8C5C-1BE74A7BAC23Q38763340-FC584FBA-C7AC-4571-8E0B-ADCEC423AEA5Q41843480-4274633E-3A57-4767-8D50-D1AC2FB028A7Q43053804-4CEC6BEF-727F-421A-A03C-CAE96E852DE7Q50483571-4F1F48A5-F4AB-4FDD-8E75-288B7457B028Q50745732-DF65B913-6E5F-4171-81E9-F14296B9D6F8Q50898003-5615683A-37DE-4D7E-B7FC-A95758D5D6F3Q53331463-FFCC2063-6B08-4DD1-87ED-47068086A85BQ53465791-506A6A34-1914-484C-A0B8-D6515FD6AF49Q54328748-03256E02-B6A1-49A4-A74B-1A078B4852C8Q56777795-D2A2FF74-FB23-499D-A6B0-D674A333ECAAQ57083775-FABE6E21-F37E-4547-9A7A-D0F537A760B7Q57083812-A431E351-36BE-4985-8935-9C6DDC125401Q81466739-721D84EF-DD04-4B11-8AC3-A1C275E44077Q85096401-F57418EC-7CB0-4514-A4DE-BAF782AB5C96Q87304618-6B60FDDA-8FEC-4665-8D51-C793AE34F370Q87766359-FD24ED19-BDF2-445E-A9A8-B2EC421A961A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Jesus Lamas
@ast
Maria Jesus Lamas
@en
Maria Jesus Lamas
@es
Maria Jesus Lamas
@nl
Maria Jesus Lamas
@sl
type
label
Maria Jesus Lamas
@ast
Maria Jesus Lamas
@en
Maria Jesus Lamas
@es
Maria Jesus Lamas
@nl
Maria Jesus Lamas
@sl
prefLabel
Maria Jesus Lamas
@ast
Maria Jesus Lamas
@en
Maria Jesus Lamas
@es
Maria Jesus Lamas
@nl
Maria Jesus Lamas
@sl
P106
P21
P31
P496
0000-0001-8875-3290